CSL Seqirus
Derived from the expression ‘securing health for all of us‘, CSL Seqirus has public health protection at its core. This reflects the promise of its parent company CSL, founded in 1916 to save lives and protect the health of people. CSL Seqirus’ first true test came with the Spanish Influenza Pandemic and this company has been committed to the fight against influenza ever since.
Influenza kills. But at CSL Seqirus, it is believed it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, CSL Seqirus works tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with other partners, this company is on the front line every day, protecting communities from seasonal influenza and global pandemic threats.
CSL Seqirus’ vision is a world protected from influenza. As a global leader in influenza protection, the company has one of the broadest influenza vaccine portfolios in the world.
Finished Products
Fluad ™ – Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted
Finished Products
Agrippal™ S1 – Influenza Vaccine (Surface Antigen, Inactivated)